Brokerages Set Immuneering Corporation (NASDAQ:IMRX) PT at $16.40

Shares of Immuneering Corporation (NASDAQ:IMRX) have received an average recommendation of “Hold” from the seven analysts that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $16.40.

A number of analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Immuneering in a report on Tuesday, September 30th. Oppenheimer boosted their price target on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. Chardan Capital boosted their price target on Immuneering from $13.00 to $20.00 and gave the company a “buy” rating in a report on Friday, September 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Immuneering in a report on Saturday. Finally, Needham & Company LLC upped their target price on Immuneering from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, September 15th.

Immuneering Trading Up 7.3%

NASDAQ:IMRX opened at $6.04 on Friday. The stock has a market cap of $251.08 million, a price-to-earnings ratio of -3.20 and a beta of 0.47. The stock has a 50-day moving average price of $6.42 and a two-hundred day moving average price of $3.86. Immuneering has a 1 year low of $1.10 and a 1 year high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.40) EPS for the quarter, meeting analysts’ consensus estimates of ($0.40). Sell-side analysts forecast that Immuneering will post -1.86 earnings per share for the current year.

Insider Transactions at Immuneering

In related news, Director Peter Feinberg bought 7,500 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The shares were acquired at an average price of $6.67 per share, for a total transaction of $50,025.00. Following the completion of the acquisition, the director owned 156,766 shares of the company’s stock, valued at approximately $1,045,629.22. The trade was a 5.02% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders bought a total of 20,800 shares of company stock worth $143,754 in the last 90 days. Corporate insiders own 22.90% of the company’s stock.

Institutional Trading of Immuneering

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after acquiring an additional 4,458 shares in the last quarter. Future Financial Wealth Managment LLC bought a new stake in Immuneering during the third quarter worth about $35,000. HighTower Advisors LLC raised its holdings in Immuneering by 17.7% during the first quarter. HighTower Advisors LLC now owns 83,960 shares of the company’s stock worth $128,000 after acquiring an additional 12,600 shares in the last quarter. Kingsview Wealth Management LLC acquired a new position in Immuneering during the second quarter worth approximately $47,000. Finally, Jane Street Group LLC acquired a new position in Immuneering during the first quarter worth approximately $32,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.